Supplement encyclopedia

Melatonin

Melatonin is a hormone involved in regulating circadian rhythms; it is also available in oral forms.

Double-check conclusions and consult the sources before choosing a supplement.

Main conclusion

What it may offer

  • For flights across five or more time zones, melatonin in the evening, around the local bedtime at the destination, may help people cope with the time change.
  • After a night shift, daytime sleep was 24 minutes longer on average, but this advantage became unclear after two studies with less reliable results were excluded. Melatonin did not help people fall asleep faster.
  • In people with a confirmed shift to a later sleep time (delayed sleep phase), 0.5 mg of melatonin together with a sleep schedule reduced time to fall asleep by 11.9 minutes over four weeks; with the same schedule, participants started sleeping 34 minutes earlier by the clock than with placebo.
  • In people aged 65–80 with insomnia, 2 mg of prolonged-release melatonin in the evening reduced time to fall asleep by 15.6 minutes over three weeks compared with placebo.
  • In adults with migraine, 3 mg of melatonin every evening over 12 weeks reduced headache days by 1.6 days per month more than placebo. In another trial, 2 mg of prolonged-release melatonin did not clearly reduce the number of attacks.
  • In middle-aged people with primary insomnia, a sleep disorder in its own right, 3 mg of immediate-release melatonin over four weeks reduced wakefulness after early waking by 30.6 minutes more than placebo; four other measured sleep outcomes did not differ convincingly.
  • In a review of studies in participants aged 5–20 with long-lasting insomnia of unknown cause, diary-reported time to fall asleep was about 18 minutes shorter and sleep 30 minutes longer compared with placebo.
  • In a small study of adults with poor sleep, Melotime capsules containing 2 mg melatonin helped people fall asleep faster, spend less time awake at night and rate their sleep better over 28 days compared with placebo; part of the difference was due to worsening in the placebo group.
  • In ten trained cyclists, 5 mg of melatonin before a ride showed no advantage in time or average power compared with placebo.

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11]

What was studied

  • Studies examined jet lag, sleep after night shifts, delayed sleep phase and insomnia in different age groups.
  • Outcomes in adults with migraine and a cycling ride in trained men were also studied separately.

[1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11]

Which forms were studied

  • Some forms release melatonin immediately, others gradually.
  • Check the composition for the form and amount of melatonin: the Melotime study used capsules containing 2 mg of melatonin.

[1] [2] [3]

How to obtain it from food

  • Melatonin has been detected in walnuts, tomatoes, strawberries, rice, barley, olive oil and milk; its content varies by food and sample.
  • For the raw walnuts studied, a calculation for 28 g of kernels yields about 98 ng of melatonin and 183 kcal. The melatonin content is the average of five samples.

[1] [2] [3]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Jet lag symptomsFor flights across five or more time zones, melatonin around local bedtime reduced jet lag in 8 of 10 trials.Reduced jet lag was reported in 8 of 10 trials; 9 trials were suitable for evaluation; NNT≈2 was calculated from only two trials.
Not assessedConfidence in the “8 out of 10” result for doses of 0.5–5 mg cannot be assessed: this count relates to mixed regimens, including 8 mg. A report of benefit at lower doses does not confirm this particular pooled proportion.
1010 trials in the reviewMelatonin for the prevention and treatment of jet lag ↗Adult travellers crossing ≥5 time zones
  1. Melatonin for the prevention and treatment of jet lag ↗
Daytime sleep duration after a shiftAfter a night shift, daytime sleep was 24 minutes longer on average, but the difference became statistically unclear after two trials at high risk of bias were excluded.Mean difference +24 minutes (95% CI +9.8…+38.9); after exclusion of two trials at high risk of bias the confidence interval crossed zero.
2/4 LowConfidence is low: in several small studies, daytime sleep after a shift was longer, but two studies had a high risk of bias, and the results of the analysis excluding them are described inconsistently. The possible increase in sleep may vary substantially in size.
77 trials in the reviewPharmacological interventions for sleepiness and sleep disturbances caused by shift work ↗263 participants in seven shift-work trials
  1. Pharmacological interventions for sleepiness and sleep disturbances caused by shift work ↗
Time to fall asleep after a shiftAfter a night shift, melatonin did not speed up sleep onset: mean difference 0.37 minutes (95% CI −1.55…+2.29) in five trials.Mean difference +0.37 minutes (95% CI −1.55…+2.29).
2/4 LowConfidence is low: data from five small trials do not show a convincing shortening of time to fall asleep, but some studies had a risk of bias and numerical estimates differ across parts of the review.
55 trials in the reviewPharmacological interventions for sleepiness and sleep disturbances caused by shift work ↗74 participants in five shift-work trials
  1. Pharmacological interventions for sleepiness and sleep disturbances caused by shift work ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Daily intake requirements and upper limits

Intake and studied regimens
ContextDetails
Intake and studied regimensDoses on this page are expressed in milligrams of melatonin itself taken orally. Timing depends on the purpose and form studied. There is no dietary RDA/AI or nutrient UL for melatonin.

Circadin 2 mg prolonged-release tablets: Summary of Product Characteristics ↗

Forms

Melatonin is a circadian-rhythm hormone; immediate and prolonged-release forms release it differently, so results from one form do not automatically transfer to another.

Guidance for each goal

Jet lag symptomsNot assessedRead moreCollapse
Confidence
Not assessedConfidence in the “8 out of 10” result for doses of 0.5–5 mg cannot be assessed: this count relates to mixed regimens, including 8 mg. A report of benefit at lower doses does not confirm this particular pooled proportion.

For flights across five or more time zones, melatonin around local bedtime reduced jet lag in 8 of 10 trials.

Study findings. For flights across five or more time zones, melatonin around local bedtime reduced jet lag in 8 of 10 trials.

Studied regimen0.5–5 mg around 22:00–00:00 local destination timeOral melatonin, preparations varied
Duration and populationAround the flight, in the evening local destination timeAdult travellers crossing ≥5 time zones

Comparison with placebo

Daytime sleep duration after a shift2/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low: in several small studies, daytime sleep after a shift was longer, but two studies had a high risk of bias, and the results of the analysis excluding them are described inconsistently. The possible increase in sleep may vary substantially in size.

After a night shift, daytime sleep was 24 minutes longer on average, but the difference became statistically unclear after two trials at high risk of bias were excluded.

Study findings. After a night shift, daytime sleep was 24 minutes longer on average, but the difference became statistically unclear after two trials at high risk of bias were excluded.

Studied regimen1–10 mg after a night shiftOral melatonin, forms varied
Duration and populationDaytime sleep after a night shift263 participants in seven shift-work trials

Comparison with placebo

Time to fall asleep after a shift2/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low: data from five small trials do not show a convincing shortening of time to fall asleep, but some studies had a risk of bias and numerical estimates differ across parts of the review.

After a night shift, melatonin did not speed up sleep onset: mean difference 0.37 minutes (95% CI −1.55…+2.29) in five trials.

Study findings. After a night shift, melatonin did not speed up sleep onset: mean difference 0.37 minutes (95% CI −1.55…+2.29) in five trials.

Studied regimen1–10 mg in the full review; regimens varied across the five trialsOral melatonin, forms varied
Duration and populationDaytime sleep after a night shift74 participants in five shift-work trials

Comparison with placebo

Time to fall asleep with delayed sleep phase3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: in a blinded study, melatonin together with a sleep schedule identical for both groups reduced time to fall asleep on average across treatment nights. The interval allows both a small and a more noticeable reduction; the result does not describe the final week separately.

With confirmed delayed sleep phase and the same sleep schedule, 0.5 mg melatonin reduced time to fall asleep by 11.9 minutes versus placebo.

Study findings. With confirmed delayed sleep phase and the same sleep schedule, 0.5 mg melatonin reduced time to fall asleep by 11.9 minutes versus placebo.

Studied regimen0.5 mg one hour before desired sleep ≥5 nights per weekImmediate-release melatonin
Duration and population4 weeks116 randomised participants with confirmed delayed phase

Comparison with placebo plus the same sleep schedule

Clock time of sleep onset3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: in a blinded study, participants taking melatonin fell asleep earlier by the clock on average, but the possible size of the shift remains wide. Both groups followed the same sleep schedule; the result does not refer separately to the final week.

With the same schedule, sleep onset occurred 34 minutes earlier by the clock than with placebo.

Study findings. With the same schedule, sleep onset occurred 34 minutes earlier by the clock than with placebo.

Studied regimen0.5 mg one hour before desired sleep ≥5 nights per weekImmediate-release melatonin
Duration and population4 weeks116 randomised participants with confirmed delayed phase

Comparison with placebo plus the same sleep schedule

Falling asleep with insomnia at ages 65–803/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: in a prespecified age subgroup of a blinded study, time to fall asleep decreased, but the confidence interval allows different sizes of improvement. The data relate to three weeks and participants aged 65–80.

In 281 participants aged 65–80 with insomnia, 2 mg prolonged-release melatonin reduced diary-reported time to fall asleep by 15.6 minutes over three weeks versus placebo.

Study findings. In 281 participants aged 65–80 with insomnia, 2 mg prolonged-release melatonin reduced diary-reported time to fall asleep by 15.6 minutes over three weeks versus placebo.

Studied regimen2 mg in the eveningProlonged-release tablet
Duration and population3 weeks281 randomised participants aged 65–80 with primary insomnia, subgroup of 791

Comparison with placebo

Days with migraine pain3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: in the study melatonin reduced the number of migraine days, but some data were lost, and missing days were counted as migraine-free in the main analysis.

In adults with migraine, 3 mg melatonin at night over 12 weeks reduced headache days by 1.6 days per month more than placebo.

Study findings. In adults with migraine, 3 mg melatonin at night over 12 weeks reduced headache days by 1.6 days per month more than placebo.

Studied regimen3 mg every eveningOral melatonin
Duration and population12 weeks119 analysed adults with migraine in the compared groups; a third amitriptyline group was separate

Comparison with placebo

Number of migraine attacks3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: in a blinded crossover study, attack frequency with melatonin did not differ convincingly from placebo, but the sample was small and the exact interval for the difference is unavailable. Absence of a significant difference does not prove equal effects.

In another eight-week trial, 2 mg prolonged-release melatonin did not clearly reduce migraine attacks versus placebo (p=0.497).

Study findings. In another eight-week trial, 2 mg prolonged-release melatonin did not clearly reduce migraine attacks versus placebo (p=0.497).

Studied regimen2 mg one hour before bedProlonged-release tablet
Duration and population8 weeks per period with a six-week washout48 randomised adults with migraine, 46 completed

Comparison with placebo

Early morning wakefulnessNot assessedRead moreCollapse
Confidence
Not assessedThe certainty of the result cannot yet be assessed: the available abstract reports a difference but does not explain how it was calculated or confirm the composition of the final analysis.

In 61 middle-aged participants with primary insomnia, 3 mg immediate-release melatonin over four weeks reduced early morning wakefulness by 30.6 minutes versus placebo.

Study findings. In 61 middle-aged participants with primary insomnia, 3 mg immediate-release melatonin over four weeks reduced early morning wakefulness by 30.6 minutes versus placebo.

Studied regimen3 mg one hour before bedImmediate release
Duration and population4 weeks61 in the final analysis (29 melatonin, 32 placebo; 97 randomised)

Comparison with placebo

Other polysomnographic sleep measuresNot assessedRead moreCollapse
Confidence
Not assessedThe certainty of the result for four sleep measures cannot yet be assessed: the available abstract does not contain the corresponding numbers and does not allow their calculation to be checked.

In the same trial, no clear difference was found in latency, total duration, wakefulness after sleep onset or sleep efficiency.

Study findings. In the same trial, no clear difference was found in latency, total duration, wakefulness after sleep onset or sleep efficiency.

Studied regimen3 mg one hour before bedImmediate release
Duration and population4 weeks61 in the final analysis (29/32)

Comparison with placebo

Falling asleep in children and adolescents3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: according to diaries in several small studies, children and adolescents fell asleep earlier, but blinding and allocation methods were inadequately described in some studies. Doses and durations varied, and the conclusion relates to short follow-up.

In children and adolescents aged 5–20 with idiopathic chronic insomnia, diary-reported time to fall asleep was 18 minutes shorter on average.

Study findings. In children and adolescents aged 5–20 with idiopathic chronic insomnia, diary-reported time to fall asleep was 18 minutes shorter on average.

Studied regimen1–10 mg in the full review; regimens differed for this outcomeOral melatonin, forms varied in the review
Duration and populationShort trials of 1–5 weeks142 children and adolescents aged 5–20

Comparison with placebo

Sleep duration in children and adolescents3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: according to diaries in several small studies, sleep duration increased, but allocation and blinding methods were insufficiently clear in some studies. This result does not establish long-term benefit or an effect on daytime well-being.

In four trials in the same group, diary-reported sleep duration was 30 minutes longer on average versus placebo.

Study findings. In four trials in the same group, diary-reported sleep duration was 30 minutes longer on average versus placebo.

Studied regimen1–10 mg in the full review; regimens differed for this outcomeOral melatonin, forms varied in the review
Duration and populationShort trials of 1–5 weeks184 children and adolescents aged 5–20

Comparison with placebo

Cycling time and power3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: in ten trained men, ride time and average power did not differ convincingly from placebo. The study was small, and absence of a significant difference does not rule out an effect on either measure.

In ten trained men, 5 mg melatonin 15 minutes before a 32.2 km cycling race did not change race time or average power versus placebo.

Study findings. In ten trained men, 5 mg melatonin 15 minutes before a 32.2 km cycling race did not change race time or average power versus placebo.

Studied regimen5 mg 15 minutes before exerciseOral melatonin
Duration and populationSingle crossover 32.2 km ride10 trained male cyclists

Comparison with placebo

Sleep efficiency3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: in a small blinded study, sleep efficiency changed in favour of melatonin, but part of the difference was related to worsening with placebo. The exact size of the effect remains uncertain.

In 59 adults aged 30–60 with poor sleep, over 28 days sleep efficiency changed by +3.49 percentage points with 2 mg prolonged-release melatonin versus −6.30 with placebo.

Study findings. In 59 adults aged 30–60 with poor sleep, over 28 days sleep efficiency changed by +3.49 percentage points with 2 mg prolonged-release melatonin versus −6.30 with placebo.

Studied regimen2 mg melatonin itself (4.44 mg granules) 30–60 minutes before bedMelotime capsule with prolonged-release granules
Duration and population28 days59 adults aged 30–60 with poor sleep who completed the study (28 melatonin, 31 placebo; 62 enrolled)

Comparison with matching placebo

Sleep duration3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: in a small blinded study, sleep duration changed in favour of melatonin; it decreased with placebo. The exact size of the benefit is difficult to assess.

In the same trial, total sleep time changed by +23.83 minutes versus −39.25 minutes with placebo.

Study findings. In the same trial, total sleep time changed by +23.83 minutes versus −39.25 minutes with placebo.

Studied regimen2 mg melatonin itself (4.44 mg granules) 30–60 minutes before bedMelotime capsule with prolonged-release granules
Duration and population28 days59 adults aged 30–60 with poor sleep who completed the study (28 melatonin, 31 placebo; 62 enrolled)

Comparison with matching placebo

Time to fall asleep3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: in a small blinded study, time to fall asleep changed in favour of melatonin, but increased with placebo. The exact size of the difference remains uncertain.

In the same trial, time to fall asleep changed by −10.28 minutes versus +16.70 minutes with placebo.

Study findings. In the same trial, time to fall asleep changed by −10.28 minutes versus +16.70 minutes with placebo.

Studied regimen2 mg melatonin itself (4.44 mg granules) 30–60 minutes before bedMelotime capsule with prolonged-release granules
Duration and population28 days59 adults aged 30–60 with poor sleep who completed the study (28 melatonin, 31 placebo; 62 enrolled)

Comparison with matching placebo

Wakefulness after sleep onset3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: in a small blinded study, time awake after sleep onset changed in favour of melatonin, but increased with placebo. The exact size of the difference remains uncertain.

In the same trial, wakefulness after sleep onset changed by −14.92 minutes versus +24.71 minutes with placebo.

Study findings. In the same trial, wakefulness after sleep onset changed by −14.92 minutes versus +24.71 minutes with placebo.

Studied regimen2 mg melatonin itself (4.44 mg granules) 30–60 minutes before bedMelotime capsule with prolonged-release granules
Duration and population28 days59 adults aged 30–60 with poor sleep who completed the study (28 melatonin, 31 placebo; 62 enrolled)

Comparison with matching placebo

PSQI sleep quality score3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: in a small blinded study, the sleep quality score improved more with melatonin, but a comparative confidence interval was not reported. The result concerns self-assessment after 28 days.

On day 28, the total PSQI sleep quality score changed by −5.61 points versus −0.65 points with placebo.

Study findings. On day 28, the total PSQI sleep quality score changed by −5.61 points versus −0.65 points with placebo.

Studied regimen2 mg melatonin itself (4.44 mg granules) 30–60 minutes before bedMelotime capsule with prolonged-release granules
Duration and population28 days59 adults aged 30–60 with poor sleep who completed the study (28 melatonin, 31 placebo; 62 enrolled)

Comparison with matching placebo

Safety and limitations

In four high-dose trials (≥10 mg, 401 participants), adverse events were more frequent: RR 1.40 (95% CI 1.15–1.69). In the same four trials, no clear difference in serious adverse events was found: RR 0.88 (95% CI 0.52–1.50). Drowsiness, headache and dizziness are possible; if drowsy, do not drive or operate machinery. Of 25 US gummy products studied, 22 differed from the label in melatonin content by more than 10%, and one contained none; this was a specific sample. In children and adolescents with idiopathic chronic insomnia, non-serious adverse events were more frequent with melatonin: RR 3.44 (95% CI 1.25–9.42), four trials, n=212. For the specific product Circadin 2 mg, the leaflet does not recommend use during pregnancy or breastfeeding because of insufficient data and likely passage into milk. The Circadin 2 mg leaflet does not recommend it for autoimmune disease or impaired liver function; it calls for caution in kidney disease. In a prolonged-release trial, new symptoms after withdrawal occurred in about 28% in both groups (p=0.881); follow-up was short. In a review of experiments in healthy adults, daytime melatonin was associated with less accurate cognitive responses (SMD −0.74; 95% CI −1.03…−0.45); this does not assess evening use. Before use in a child or adolescent, discuss melatonin with a paediatrician: long-term safety has not been adequately studied. With epilepsy, melatonin use requires medical supervision. In a small trial in 17 men with type 2 diabetes, 10 mg melatonin before bed over 12 weeks reduced insulin sensitivity relative to placebo. In 21 healthy women, a single 5 mg dose 15 minutes before a test with 75 g glucose worsened glucose tolerance in the morning and evening. If you have diabetes, agree on use with your treating doctor.

Safety of higher doses of melatonin in adults: A systematic review and meta-analysis ↗ · Circadin 2 mg prolonged-release tablets: Summary of Product Characteristics ↗ · Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US ↗ · Use of melatonin in children and adolescents with idiopathic chronic insomnia: a systematic review, meta-analysis, and clinical recommendation ↗ · Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety ↗ · Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer’s disease and insomnia: A systematic review and meta-analysis of randomized controlled trials ↗ · Melatonin: What You Need To Know ↗ · Melatonin: a medicine used for sleep problems - NHS ↗ · Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes-A randomized placebo-controlled crossover trial. ↗ · Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. ↗

Interactions

WithEffectActionSource
FluvoxamineThe Circadin 2 mg leaflet reports a 17-fold increase in melatonin AUC and a 12-fold increase in peak concentration.The combination with Circadin should be avoided; discuss treatment with a doctor.Circadin 2 mg prolonged-release tablets: Summary of Product Characteristics ↗
ZolpidemIn a trial, co-administration of Circadin 2 mg impaired attention, memory and coordination more than zolpidem alone.Before taking them together, discuss the risk of drowsiness and impairment with a doctor.Circadin 2 mg prolonged-release tablets: Summary of Product Characteristics ↗
NifedipineIn 47 participants with controlled hypertension, 5 mg melatonin in the evening over four weeks increased mean 24-hour blood pressure relative to placebo.Before taking them together, discuss blood pressure monitoring with a doctor.Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study ↗
Warfarin and other anticoagulantsAuthoritative references recommend monitoring during combined use; bleeding frequency is not established by these data.Before combined use, agree on melatonin with the doctor overseeing anticoagulant treatment.Melatonin: a medicine used for sleep problems - NHS ↗
Melatonin: What You Need To Know ↗

Food sources

Measured melatonin is shown, not tryptophan or serotonin. The walnut value is the average of five raw samples studied; food content varies.

Vegetables and fruit

Melatonin has been measured, for example, in tomatoes and strawberries; values differ between samples.

Dietary factors and fluctuating levels of melatonin ↗

Nuts

Melatonin has been detected in walnuts.

Dietary factors and fluctuating levels of melatonin ↗

Cereals

Measurements of melatonin have been reported in rice and barley.

Dietary factors and fluctuating levels of melatonin ↗

Other foods

Melatonin has been detected in olive oil and milk; content depends on the product.

Dietary factors and fluctuating levels of melatonin ↗

Food composition

FoodGroupAmountServingCaloriesSources
Walnutraw kernels, mixed varieties; average of five samplesNuts350 ng melatonin, approximately / 100 g28 g · 98 ng melatonin, approximately · 183.12 kcalAbout seven walnuts in shell: 28 g edible kernels according to USDA.654 kcal / 100 gMelatonin in walnuts: influence on levels of melatonin and total antioxidant capacity of blood ↗
USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Nut and Seed Products ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Melatonin for the prevention and treatment of jet lag ↗systematic review and meta-analysisJet lag symptomsAdult travellers crossing ≥5 time zonesOral melatonin, preparations varied; 0.5–5 mg around 22:00–00:00 local destination time; Around the flight, in the evening local destination time; comparison: PlaceboFor flights across five or more time zones, melatonin around local bedtime reduced jet lag in 8 of 10 trials.
Pharmacological interventions for sleepiness and sleep disturbances caused by shift work ↗systematic review and meta-analysisDaytime sleep duration after a shift: Daytime sleep duration after a shift Time to fall asleep after a shift: Time to fall asleep after a shiftDaytime sleep duration after a shift: 263 participants in seven shift-work trials Time to fall asleep after a shift: 74 participants in five shift-work trialsDaytime sleep duration after a shift: Oral melatonin, forms varied; 1–10 mg after a night shift; Daytime sleep after a night shift; comparison: Placebo Time to fall asleep after a shift: Oral melatonin, forms varied; 1–10 mg in the full review; regimens varied across the five trials; Daytime sleep after a night shift; comparison: PlaceboDaytime sleep duration after a shift: After a night shift, daytime sleep was 24 minutes longer on average, but the difference became statistically unclear after two trials at high risk of bias were excluded. Time to fall asleep after a shift: After a night shift, melatonin did not speed up sleep onset: mean difference 0.37 minutes (95% CI −1.55…+2.29) in five trials.

Sources

Sources
  1. Melatonin for the prevention and treatment of jet lag ↗
  2. Pharmacological interventions for sleepiness and sleep disturbances caused by shift work ↗
  3. Efficacy of melatonin with behavioural sleep-wake scheduling for delayed sleep-wake phase disorder: A double-blind, randomised clinical trial ↗
  4. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety ↗
  5. Randomised clinical trial comparing melatonin 3 mg, amitriptyline 25 mg and placebo for migraine prevention ↗
  6. Prophylaxis of migraine with melatonin: a randomized controlled trial ↗
  7. Efficacy of melatonin for sleep disturbance in middle-aged primary insomnia: a double-blind, randomised clinical trial ↗
  8. Use of melatonin in children and adolescents with idiopathic chronic insomnia: a systematic review, meta-analysis, and clinical recommendation ↗
  9. Consumption of a 5-mg Melatonin Supplement Does Not Affect 32.2-km Cycling Time Trial Performance ↗
  10. Efficacy and Safety of Sustained-Release Melatonin Capsules (2 mg) in Healthy Adults with Poor Sleep Quality: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
  11. Circadin 2 mg prolonged-release tablets: Summary of Product Characteristics ↗
  12. Dietary factors and fluctuating levels of melatonin ↗
  13. Safety of higher doses of melatonin in adults: A systematic review and meta-analysis ↗
  14. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study ↗
  15. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US ↗
  16. Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer’s disease and insomnia: A systematic review and meta-analysis of randomized controlled trials ↗
  17. Melatonin in walnuts: influence on levels of melatonin and total antioxidant capacity of blood ↗
  18. USDA National Nutrient Database for Standard Reference, Release 28 (2015) — Nut and Seed Products ↗
  19. Melatonin for the Treatment of Insomnia: A 2022 Update: Rapid Review [Internet] — Table 12 ↗
  20. Melatonin: What You Need To Know ↗
  21. Melatonin: a medicine used for sleep problems - NHS ↗
  22. Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes-A randomized placebo-controlled crossover trial. ↗
  23. Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. ↗